GenScript ProBio Extends Drug Development Collaboration with REMB

GenScript Pro B io, a Nanjing CDMO, agreed to license a bispecific antibody to REMD Bio for an undisclosed target. REMD is a clinical stage San Francisco-Beijing biologics company.  REMD will pay GenScript ProBio service fees, commercialization milestones and royalties. The bispecific antibody is derived from single-domain antibody fused to GenScript's monoclonal antibody (SMAB) platform. In 2019, the two companies formed a collaboration to develop several novel bispecific cancer immunotherapy candidates. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.